Document registry — page 33
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised crossover, phase 1 study of Liraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low15 Dec 2023 -
Randomised crossover, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low14 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low14 Dec 2023 -
43-residue actin-sequestering polypeptide. Thymosin beta-4 sequesters monomeric actin and thereby regulates cytoskeletal dynamics, cell migration and wound repair. Extracellular administration…
Low13 Dec 2023 -
Single-arm open-label, phase 3 study of Teduglutide in mucosal barrier randomising 59 participants over 24 weeks. Primary result: A reduction in parenteral support…
Moderate13 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of GHRP-6 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low13 Dec 2023 -
Consultation on the draft standard specifying the minimum data a certificate of analysis must carry before the Institute will treat it as interpretable. The draft…
12 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing randomising 72 participants over 4 weeks. Primary result: Improvement in…
Low12 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low12 Dec 2023 -
Single-arm open-label, phase 3 study of Tirzepatide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low12 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low12 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low11 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low09 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes and chronic kidney disease over as stated in the parent protocol. The…
Very low09 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes over as stated in the parent protocol. The…
Very low07 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes over as stated in the parent…
Very low07 Dec 2023 -
Observational, phase 3 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Orforglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low05 Dec 2023 -
Randomised crossover, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Dec 2023 -
Single-arm open-label, phase 3 study of Exenatide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low03 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Ipamorelin in gastric emptying over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low03 Dec 2023 -
Single-arm open-label, phase 2 study of Glutathione in cognition over open-label extension of the parent trial. The Institute holds no reported primary result for this…
Very low29 Nov 2023 -
Randomised crossover, phase 1 study of Liraglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low26 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low25 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity randomising 806 participants over 72 weeks after a 12-week lead-in. Primary result…
High24 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low24 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no…
Very low24 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in adolescent obesity randomising 251 participants over 56 weeks. Primary result: Estimated…
Moderate23 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of GHRP-2 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low23 Nov 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes randomising 9,463 participants over median 1.6 years…
Moderate22 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low22 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 1/2 study of LL-37 in wound healing randomising 34 participants over 4 weeks. Primary result: A dose-dependent…
Low21 Nov 2023 -
Single-arm open-label, phase 3 study of Dulaglutide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low21 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and chronic kidney disease and type 2 diabetes over as stated in the parent…
Very low21 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low21 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Hexarelin in lean-mass preservation over 16 weeks. Primary result: Tachyphylaxis of the growth-hormone…
Low20 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low20 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low20 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low19 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low19 Nov 2023
page 33 of 41